| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 01/31/2008 | WO2008013257A1 Monoclonal antibody to soluble lox-1 |
| 01/31/2008 | WO2008012941A1 Method for diagnosis of heart failure |
| 01/31/2008 | WO2008012543A1 Single chain fc polypeptides |
| 01/31/2008 | WO2008012503A1 Homologue of pro4426 |
| 01/31/2008 | WO2008012049A1 Post-translationally modified neurotrophins |
| 01/31/2008 | WO2008011711A1 Cancerous disease modifying antibodies |
| 01/31/2008 | WO2007136856A3 Heyl as a therapeutic target and a diagnostic marker for neoplasia and uses therefor |
| 01/31/2008 | WO2007049017A3 Agents that bind a target in pulmonary tissue for treating respiratory diseases |
| 01/31/2008 | WO2007033096A3 Methods and compositions for diagnosis and treatment of disorders involving macrophages |
| 01/31/2008 | WO2005118646A3 Epitope directed selection of antibodies to murine tissue factor |
| 01/31/2008 | US20080027148 Drug targets related to synthase subfamily; alternative splice forms; isolated peptides and antibodies |
| 01/31/2008 | US20080027147 polypeptides for use in the diagnosis and treatment of cell proliferative disorders |
| 01/31/2008 | US20080027130 Cytotoxic agents comprising taxanes and their therapeutic use |
| 01/31/2008 | US20080027106 Methods of treating psychosis and schizphrenia based on polymorphisms in the cntf gene |
| 01/31/2008 | US20080027020 Human Neuropeptide Receptor |
| 01/31/2008 | US20080027005 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/31/2008 | US20080027004 Phosphorylated COP1 molecules and uses thereof |
| 01/31/2008 | US20080027001 Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same |
| 01/31/2008 | US20080026992 Tyrosine Phosphorylation of Cdk Inhibitor Proteins of the Cip/Kip Family |
| 01/31/2008 | US20080026982 Mutant APOBEC3G molecules for inhibiting replication of HIV |
| 01/31/2008 | US20080026980 Use of Agents Derived from Ceacam1 for the Treatment of Inflammatory Diseases |
| 01/31/2008 | US20080026948 Protein (poly)peptides libraries |
| 01/31/2008 | US20080026480 Detection systems for mass labels |
| 01/31/2008 | US20080026458 CHIMERIC AND HUMANIZED ANTIBODIES TO alpha5beta1 INTEGRIN THAT MODULATE ANGIOGENESIS |
| 01/31/2008 | US20080026427 HUMAN cDNAs AND PROTEINS AND USES THEREOF |
| 01/31/2008 | US20080026414 Method for the Determination of the Formation of Endothelins for Medical Diagnostic Purposes, and Antibodies and Kits for Carrying Out Such a Method |
| 01/31/2008 | US20080026404 G-protein coupled receptor for use in identifying modulators of taste perception in mammals; improving the palatability of low-calorie beverages |
| 01/31/2008 | US20080026402 Hematopoietin receptors HPR1 and HPR2 |
| 01/31/2008 | US20080026399 treating bladder and lower urinary tract syndromes particularly irrative symptoms using alpha 1d-adrenergic receptor ( alpha 1dAR) antagonists; drug screening |
| 01/31/2008 | US20080026384 Methods and compositions for the detection of bovine pregnancy |
| 01/31/2008 | US20080026363 Acetyl coa carboxylase 2 sequences and methods |
| 01/31/2008 | US20080026033 CHIMERIC AND HUMANIZED ANTIBODIES TO alpha5beta1 INTEGRIN THAT MODULATE ANGIOGENESIS |
| 01/31/2008 | US20080026000 Nicotine hapten where nicotine in which the pyrrolidine ring is substituted by an omega-carboxy-, -amino-, -formyl- or -mercapto-alkyl group; useful in formulating vaccines for active immunization; preventing nicotine addiction |
| 01/31/2008 | US20080025999 Yersinia species compositions |
| 01/31/2008 | US20080025993 Method for Refolding Neisserial Nspa Protein |
| 01/31/2008 | US20080025990 anti-IGFR1 antibodies; combination with topoisomerase inhibitor such as irinotecanp; antitumor |
| 01/31/2008 | US20080025988 Monoclonal Antibody And Use Thereof |
| 01/31/2008 | US20080025986 Methods of Treating Tnf-Mediated Disorders |
| 01/31/2008 | US20080025985 Method of treating a pathological syndrome and a pharmaceutical agent |
| 01/31/2008 | US20080025983 Methods of screening based on the EGF receptor crystal structure |
| 01/31/2008 | US20080025982 Uses of Sperm Membrane Protein Obf |
| 01/31/2008 | US20080025981 Cancer-linked genes as targets for chemotherapy |
| 01/31/2008 | US20080025980 which binds to B lymphoblastoid cells and induces proliferation and activation of peripheral blood lymphocytes; anti-tumor effect when injected into a tumor-bearing subject; HIV infection or AIDS (Acquired Immune Deficiency Syndrome) |
| 01/31/2008 | US20080025979 Programmed Death 1(PD-1); bispecific antibodies comprising antibodies against human T cell receptor complex or human B cell receptor complex; autoimmune diseases |
| 01/31/2008 | US20080025977 Cytotoxicity mediation of cells evidencing surface expression of CD59 |
| 01/31/2008 | US20080025976 Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
| 01/31/2008 | US20080025975 Humanized antibodies against cd3 |
| 01/31/2008 | US20080025974 Toll-like receptor polypeptides for generating atibodies for use in treatment and prevention of septic shock, inflammation and viral infection |
| 01/31/2008 | US20080025971 Antibody comprising a human heavy chain framework sequence, three heavy chain hypervariable region sequences and three light chain hypervariable region sequences; modulating biological activity of integrins containing the beta7 subunit |
| 01/31/2008 | US20080025968 Methods and Agents for Immune Modulation and Methods for Identifying Immune Modulators |
| 01/31/2008 | US20080025913 Novel Anti-Dc-Sign Antibodies |
| 01/31/2008 | CA2666515A1 Cancerous disease modifying antibodies |
| 01/31/2008 | CA2660947A1 Monoclonal antibody to soluble lox-1 |
| 01/31/2008 | CA2658824A1 Compositions and methods for diagnosing patients with acute atherosclerotic syndromes |
| 01/31/2008 | CA2658542A1 Single chain fc polypeptides |
| 01/31/2008 | CA2657563A1 Post-translationally modified neurotrophins |
| 01/31/2008 | CA2619983A1 Fully human hybridoma fusion partner cell lines |
| 01/30/2008 | EP1882698A1 Design of interferon-inducible protein-10 (IP10 or CXCL10) chemokine analogs for the treatment of human diseases |
| 01/30/2008 | EP1882697A1 Post-translationally modified neurotrophins |
| 01/30/2008 | EP1882696A2 PRRSV antigenic sites identifying peptide sequences of PRRS virus for use in vaccines or diagnostic assays |
| 01/30/2008 | EP1882047A2 Compositions, methods and kits for real-time nucleic acid analysis in live cells |
| 01/30/2008 | EP1882035A2 Genes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy |
| 01/30/2008 | EP1881993A2 Nebulization of monoclonal antibodies for treating pulmonary diseases |
| 01/30/2008 | EP1881843A2 Kinase peptides and antibodies |
| 01/30/2008 | CN101115847A Methods of detecting an analyte in a sample |
| 01/30/2008 | CN101115773A Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof |
| 01/30/2008 | CN101115772A Cytotoxic antibody directed against type-B lymphoid haematopoietic prolifeeations |
| 01/30/2008 | CN101115771A 人类抗体和蛋白质 Human antibodies and proteins |
| 01/30/2008 | CN101113450A Neurotrophic factor |
| 01/30/2008 | CN101113449A Neurotrophic factor |
| 01/30/2008 | CN101113177A Method for separating and purifying anti-hepatitis B immune globulin from plasma or plasma component |
| 01/30/2008 | CN101113176A Method for preparing infectious chicken Fabricius bursa refined yolk cryodesiccation antibody |
| 01/30/2008 | CN101113170A Preparation of new gene cell cycle related tumour high-expression gene monoclonal antibody and its application |
| 01/30/2008 | CN101113163A Hla-a24-restricted cancer antigen peptides |
| 01/30/2008 | CN100365120C Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/30/2008 | CN100365021C Nucleic protein 'Shoca'-a component of wnt signal transmission channel |
| 01/30/2008 | CN100365017C Antigenic polypeptide of chlamydia pneumoniae |
| 01/30/2008 | CN100364612C Degraded agonist antibody |
| 01/30/2008 | CN100364499C Zinc-containing sustained-release composition, its preparation, and method for producing the same |
| 01/30/2008 | CA2654911A1 Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists |
| 01/29/2008 | US7323553 Non-affinity purification of proteins |
| 01/29/2008 | US7323552 Genetic engineering; diagnosis of antiinflammatory agents |
| 01/29/2008 | US7323551 Compositions and methods for inhibiting squamous cell carcinoma |
| 01/29/2008 | US7323550 Anti-PRO4318 antibodies |
| 01/29/2008 | US7323549 IL-7 fusion proteins |
| 01/29/2008 | US7323548 Antibodies or active fragments specific for MORT-1 (Mediator of Receptor Toxicity) protein having amino acid sequence 2; tumors, hiv |
| 01/29/2008 | US7323545 PRO1885 polypeptides |
| 01/29/2008 | US7323544 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferative and tumor disorders |
| 01/29/2008 | US7323440 De-immunized MOG (poly)peptide constructs |
| 01/29/2008 | US7323331 Method for detecting or assaying HBV |
| 01/29/2008 | US7323327 Genes encoding novel proteolytic enzymes |
| 01/29/2008 | US7323324 N-Acetylglucosamine transferase, nucleic acid encoding the same, antibody against the same and use thereof for diagnosing cancer or tumor |
| 01/29/2008 | US7323311 Methods of obtaining a specific binding member that binds eotaxin |
| 01/29/2008 | US7323179 Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections |
| 01/29/2008 | US7323175 Immunogenicity of glucan binding protein |
| 01/29/2008 | US7323173 Administration of phosphorylated Mammastatin having a molecular weight of 53 kDa or 49 kDa; the polypeptide is specifically reactive with monoclonal antibody 7G6 that is produced from hybridoma ATCC No. HB10152 |
| 01/29/2008 | US7323172 Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| 01/29/2008 | US7323171 less immunosuppression than pre-existing therapies; anti-LFA-3 antibody homologs, anti-CD2 antibody homologs, soluble LFA-3 polypeptides, small molecules, e.g., carbohydrates, soluble CD2 polypeptides, CD2 or LFA-3 mimetic agents and derivatives |
| 01/29/2008 | US7323170 Anti-CD80 antibodies |
| 01/29/2008 | US7323168 Immunotherapy for chronic myelocytic leukemia |